Advertisement


Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes

2018 ASCO Annual Meeting

Advertisement

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.



Related Videos

Kidney Cancer

Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial

Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).

Skin Cancer

Paolo A. Ascierto, MD, on Melanoma: Results From the COLUMBUS Trial

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses phase III study findings on encorafenib plus binimetinib vs vemurafenib or encorafenib in BRAF-mutant melanoma (Abstract 9504).

Gynecologic Cancers

Martee L. Hensley, MD, on Leiomyosarcoma: Results From a GOG Treatment Trial

Martee L. Hensley, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on adjuvant gemcitabine plus docetaxel followed by doxorubicin vs observation for uterus-limited, high-grade leiomyosarcoma (Abstract 5505).

Leukemia

Robert J. Kreitman, MD, on Hairy Cell Leukemia: Results From an International Study

Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).

Multiple Myeloma

Aviva C. Krauss, MD, on Multiple Myeloma: Treatment Trials Analysis

Aviva C. Krauss, MD, of the U.S. Food and Drug Administration, discusses findings on an FDA analysis of immune-related adverse events and response to pembrolizumab in multiple myeloma (Abstract 8008).

Advertisement

Advertisement




Advertisement